NCT03931317View on ClinicalTrials.gov

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

May 20, 2021

Study Completion Date

March 1, 2023

Conditions
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
Interventions
DRUG

Latanoprostene bunod 0.024% QD

This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.

DRUG

Timolol maleate 0.5% BID

This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.

Trial Locations (1)

92093

UCSD Shiley Eye Institute, La Jolla

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

University of California, San Diego

OTHER

NCT03931317 - Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity | Biotech Hunter | Biotech Hunter